Biotechnology

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

Global CRO ChemPartner launches a new research site in Kent's Discovery Park, a major strategic push to accelerate drug development for European clients.

A new national scholarship from longevity expert Dr. Sajad Zalzala aims to empower future healthcare professionals to tackle the root causes of disease.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

The Norwegian innovator reports strong operational progress but faces uncertainty as a crucial NOK 158 million share placement is delayed until Q2 2026.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

Dr. Lisa G. Roth, a top oncologist and survivor, takes the helm at Hassenfeld, promising a new era of 'whole person' care for young cancer patients.

A landmark partnership is scaling a 'one-drug, many-diseases' therapy, revealing how logistics, not just labs, are key to the future of medicine.

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

A $520K state grant will provide firefighters with a new AI-powered blood test, highlighting a major push to protect high-risk first responders.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

FDA greenlights a novel, AI-discovered therapy for a Phase 1 trial, offering new hope for children with devastating central nervous system tumors.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Biotech pioneer Stratum Biosciences lands $2M seed funding to scale its AI platform, mining 200,000 skin samples to unlock new frontiers in dermatology.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.